Schor Chen bought $15,150 worth of shares (11,000 units at $1.38), covered exercise/tax liability with 23,208 shares and sold $15,291 worth of shares (11,000 units at $1.39), decreasing direct ownership by 13% to 153,761 units (SEC Form 4)
$ACET
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 09/28/2023 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
|||||||||||||||||||||||||
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 09/28/2023 | S(1) | 5,500 | D | $1.42 | 37,969 | I | See Footnote(2) | ||
| Common Stock | 09/28/2023 | P(1) | 5,500 | A | $1.42 | 182,469 | D | |||
| Common Stock | 09/29/2023 | S(1) | 5,500 | D | $1.3601(3) | 176,969 | D | |||
| Common Stock | 10/02/2023 | P(1) | 5,500 | A | $1.3345(4) | 43,469 | I | See Footnote(2) | ||
| Common Stock | 10/02/2023 | F(5) | 23,208 | D | $1.37 | 153,761 | D | |||
| Common Stock | 53,424 | I | See Footnote(6) | |||||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Explanation of Responses: |
| 1. The transactions reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person will promptly and voluntarily disgorge to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act. |
| 2. Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee. |
| 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $1.33 to $1.38, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission ("SEC") staff upon request. |
| 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $1.32 to $1.35, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. |
| 5. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. |
| 6. Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee. |
| Remarks: |
| /s/ Nick Harvey, Attorney-in-Fact | 10/02/2023 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||